Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From MedImmune LLC
To date this year, not a single innovative drug-focused biotech has filed for an initial public offering on the Science and Technology Innovation Board of the Shanghai Stock Exchange. Apart from a suspected tightening of listing rules, IPO disclosures and the plummeting share prices of public companies seem to be looming large over bioventures aiming considering floating on the bourse.
National Resilience, Parker Institute team to incubate cancer startups. Metropolitan AntiViral Drug Accelerator will focus on eight molecular features of SARS-CoV-2 to create novel oral antivirals.
The German firm is buying Frame Cancer Therapeutics in a deal valued at €32m, with CEO Franz-Werner Haas claiming that it will help the firm in its search for promising neoantigens for its mRNA cancer vaccine programs.
With GABA-A modulator PRAX-114 missing all endpoints in a monotherapy study, Praxis will cease development of that drug and focus on its candidates for essential tremor and epilepsy.
- Large Molecule